258 related articles for article (PubMed ID: 34289897)
21. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
Schade AE; Schieven GL; Townsend R; Jankowska AM; Susulic V; Zhang R; Szpurka H; Maciejewski JP
Blood; 2008 Feb; 111(3):1366-77. PubMed ID: 17962511
[TBL] [Abstract][Full Text] [Related]
22. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
23. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
24. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML
Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139
[TBL] [Abstract][Full Text] [Related]
25. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
Sun C; Shou P; Du H; Hirabayashi K; Chen Y; Herring LE; Ahn S; Xu Y; Suzuki K; Li G; Tsahouridis O; Su L; Savoldo B; Dotti G
Cancer Cell; 2020 Feb; 37(2):216-225.e6. PubMed ID: 32004441
[TBL] [Abstract][Full Text] [Related]
26. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction.
Lamarthée B; Marchal A; Charbonnier S; Blein T; Leon J; Martin E; Rabaux L; Vogt K; Titeux M; Delville M; Vinçon H; Six E; Pallet N; Michonneau D; Anglicheau D; Legendre C; Taupin JL; Nemazanyy I; Sawitzki B; Latour S; Cavazzana M; André I; Zuber J
Nat Commun; 2021 Nov; 12(1):6446. PubMed ID: 34750385
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.
Davis CC; Marti LC; Sempowski GD; Jeyaraj DA; Szabolcs P
Cancer Res; 2010 Jul; 70(13):5249-58. PubMed ID: 20530666
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic control of CAR-T cell function using dasatinib.
Weber EW; Lynn RC; Sotillo E; Lattin J; Xu P; Mackall CL
Blood Adv; 2019 Mar; 3(5):711-717. PubMed ID: 30814055
[TBL] [Abstract][Full Text] [Related]
29. Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling.
Nair S; Wang JB; Tsao ST; Liu Y; Zhu W; Slayton WB; Moreb JS; Dong L; Chang LJ
Curr Gene Ther; 2019; 19(1):40-53. PubMed ID: 30444200
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
32. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.
Ramakrishna S; Highfill SL; Walsh Z; Nguyen SM; Lei H; Shern JF; Qin H; Kraft IL; Stetler-Stevenson M; Yuan CM; Hwang JD; Feng Y; Zhu Z; Dimitrov D; Shah NN; Fry TJ
Clin Cancer Res; 2019 Sep; 25(17):5329-5341. PubMed ID: 31110075
[TBL] [Abstract][Full Text] [Related]
33. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists.
Petersen CT; Hassan M; Morris AB; Jeffery J; Lee K; Jagirdar N; Staton AD; Raikar SS; Spencer HT; Sulchek T; Flowers CR; Waller EK
Blood Adv; 2018 Feb; 2(3):210-223. PubMed ID: 29386194
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract][Full Text] [Related]
35. Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia.
Heng G; Jia J; Li S; Fu G; Wang M; Qin D; Li Y; Pei L; Tian X; Zhang J; Wu Y; Xiang S; Wan J; Zhu W; Zhang P; Zhang Q; Peng X; Wang L; Wang P; Wei Z; Zhang Y; Wang G; Chen X; Zhang C; Sun Y; Zhao W; Fan Y; Yang Z; Chen J; Qian C
Clin Cancer Res; 2020 Apr; 26(7):1606-1615. PubMed ID: 31732519
[TBL] [Abstract][Full Text] [Related]
36. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
Weichsel R; Dix C; Wooldridge L; Clement M; Fenton-May A; Sewell AK; Zezula J; Greiner E; Gostick E; Price DA; Einsele H; Seggewiss R
Clin Cancer Res; 2008 Apr; 14(8):2484-91. PubMed ID: 18413841
[TBL] [Abstract][Full Text] [Related]
37. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
38. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
39. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
Stock S; Schmitt M; Sellner L
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]